US Patent 5,630,796: Scope, Claims, Expiration, and Powdered-Drug Transdermal Patent Landscape

US Patent 5,630,796 covers a needle-free method for delivering powdered therapeutic particles through mammalian skin at high velocity. Its independent claims require defined particle-size and delivery-performance parameters. The patent does not claim a particular injector, drug composition, disease indication, or manufacturing process. The patent has expired, so its claims no longer create a current US exclusion right.

What does US Patent 5,630,796 protect?

US Patent 5,630,796, titled “Transdermal delivery of powdered medicaments,” protects a method of therapeutic treatment in which powdered drug particles are accelerated across skin tissue. The core concept is mechanical penetration of the skin by particles rather than delivery through a conventional needle, patch, liquid jet, or passive diffusion system (U.S. Patent No. 5,630,796, 1997).

The principal claim elements are:

Claim element	Requirement
Therapeutic activity	Delivery must be part of a method of therapeutic treatment
Route	Particles must cross skin tissue transdermally
Subject	Mammalian subject; dependent claims specify humans
Drug form	Powdered therapeutic agent
Particle size	Predominantly about 10 to 250 micrometers
Velocity alternative	200 to 2,500 meters per second
Narrower velocity ranges	500 to 1,500 m/s and 750 to 1,000 m/s
Density alternative	0.1 to 25 g/cm³
Momentum-density alternative	2 to 10 kg/sec/m
Drug-carrier alternative	Therapeutic agent combined with an inert carrier or diluent
Specific embodiments	Insulin, stable dry mixtures, and spherical-shell particles

The claims are method claims. They generally require proof that the accused delivery event actually meets the particle and propulsion parameters.

How do the independent claims differ?

Claims 1, 10, 13, and 14 are the principal claim groups.

Claim 1: velocity and density

Claim 1 requires all of the following:

A therapeutic treatment;
Transdermal delivery of powdered therapeutic particles;
Delivery velocity of 200 to 2,500 m/s;
Particle size predominantly between about 10 and 250 micrometers; and
Particle density between 0.1 and 25 g/cm³.

Claims 2 through 9 narrow this group. The dependent claims specify narrower velocity ranges, smaller particle sizes, lower density, human treatment, insulin, spherical shells, and dry mixtures of drugs that are unstable when mixed in a wet state.

Claim 10: momentum density

Claim 10 replaces the velocity-and-density combination with a momentum-density limitation. It requires particles predominantly sized between 10 and 250 micrometers and delivered at a momentum density of 2 to 10 kg/sec/m.

Claim 11 narrows the momentum-density range to 4 to 7 kg/sec/m. Claim 12 limits the subject to a human.

This claim group is materially different from claim 1. A product or process might satisfy the momentum-density limitation without falling within the claimed velocity and density combination, although the relevant physical measurements would need to be established.

Claims 13 and 14: inert carrier or diluent

Claims 13 and 14 add a formulation requirement: the therapeutic powder must be combined with an inert carrier or diluent.

Claim 13 uses the velocity-and-density framework. Claim 14 uses the momentum-density framework. These claims are narrower than claims 1 and 10 because they require the additional carrier or diluent.

What formulations are protected by US 5,630,796?

The patent covers dry particulate formulations suitable for high-speed transdermal delivery. The claims expressly identify:

Powdered therapeutic agents;
Therapeutic particles combined with an inert carrier or diluent;
Stable dry mixtures of drugs that are unstable when mixed in wet form;
Insulin-containing particles; and
Spherical-shell particles.

The patent does not claim every dry powder formulation. The claimed powder must be used in the specified transdermal treatment method and must satisfy the applicable size, velocity, density, or momentum-density limitations.

The insulin limitation in claim 7 does not create a broad insulin patent. It covers insulin only when used in the claimed high-velocity particle-delivery method. It does not cover insulin itself, insulin analogs generally, insulin formulations delivered by injection, or conventional transdermal insulin patches.

How should the particle-size language be interpreted?

The phrase “predominantly in the range of about 10 to 250 μm” creates a distribution-based limitation rather than an absolute requirement that every particle fall within the range.

A technical infringement analysis would likely examine:

Particle-size distribution;
The proportion of particles within the claimed range;
Measurement method and sampling conditions;
Whether agglomerates are counted as single particles;
Whether the formulation changes during acceleration; and
Whether the relevant particles are the therapeutic particles or carrier particles.

The claims do not state a numerical threshold for “predominantly.” That term could create factual disputes over the applicable percentage and measurement protocol. The patent’s specification and prosecution history would be important in determining whether the term received a limiting construction.

What velocity and momentum requirements create the main infringement risk?

The main technical issue is whether velocity is measured at the delivery locus, rather than at the device outlet. Claim 1 requires delivery “to the locus of transdermal administration” at the specified velocity. A device that accelerates particles to a high exit velocity but loses substantial velocity before impact could present a different infringement question.

The velocity ranges are broad:

Claim group	Claimed performance
Claim 1	200 to 2,500 m/s
Claim 2	500 to 1,500 m/s
Claim 3	750 to 1,000 m/s
Claim 10	Momentum density of 2 to 10 kg/sec/m
Claim 11	Momentum density of 4 to 7 kg/sec/m

The momentum-density claims may require reconstruction of the measurement methodology because “kg/sec/m” is not a commonly used commercial specification for transdermal injector products. Particle mass, particle flux, impact area, and time interval may all affect the calculation.

When did US Patent 5,630,796 lose exclusivity?

The patent’s US statutory term ended in 2015. The application was filed after the effective date of the Uruguay Round Agreements Act patent-term changes, making the relevant framework generally 20 years from the earliest effective US nonprovisional filing date, subject to patent-term adjustment and other recorded term events (35 U.S.C. § 154).

Event	Date or status
Patent issued	May 20, 1997
Patent number	US 5,630,796
Expected statutory expiration	2015
Current enforceability	Expired
Current US blocking right	None based on this patent

The patent cannot support a new US infringement action for conduct occurring after expiration. Historical infringement claims may remain subject to applicable limitation periods, releases, settlements, and other procedural rules, but the patent is no longer a prospective barrier to commercialization.

What is the Orange Book status of US 5,630,796?

US Patent 5,630,796 is not an Orange Book drug patent in the ordinary sense. The Orange Book lists patents submitted for approved drug products, including patents covering drug substances, drug products, and certain approved methods of use under FDA listing rules (FDA, 2024).

This patent claims a delivery method rather than a specific approved drug product. It is not a patent on insulin, a particular insulin analog, or an approved drug-device combination. Its expiration also removes any current Orange Book-based exclusivity significance.

A current product using high-velocity powder delivery would require separate analysis of:

The approved therapeutic product;
Any listed formulation or method-of-use patents;
Device clearance or approval;
Combination-product requirements; and
Later patents directed to the injector or formulation.

Were Paragraph IV challenges or generic litigation associated with this patent?

The patent was not a conventional small-molecule Orange Book composition patent, so a Paragraph IV challenge would not ordinarily target it as the primary barrier to an ANDA. Paragraph IV litigation generally concerns patents listed for an approved reference drug under the Hatch-Waxman framework (21 U.S.C. § 355).

The patent’s commercial relevance was instead tied to needle-free delivery technology and potential device-drug combinations. Any historical dispute would more likely involve patent infringement, ownership, licensing, or freedom-to-operate issues than a conventional generic-drug Paragraph IV case.

No current Paragraph IV risk attaches to this expired patent.

Which companies were associated with the powdered-drug delivery platform?

The patent family is associated with the PowderJect technology platform. PowderJect Pharmaceuticals developed needle-free delivery systems for powders, vaccines, and other therapeutic agents. Chiron acquired PowderJect in 2003. Novartis acquired Chiron in 2006, bringing the PowderJect assets into the Novartis portfolio (Novartis AG, 2006).

The commercial landscape later included other needle-free and particle-delivery companies, including:

PharmaJet, focused primarily on liquid jet injection;
Bioject, associated with needle-free injection systems;
PowderMed, focused on powder-based vaccine delivery; and
Device manufacturers developing gas-powered or ballistic particle injectors.

These companies’ later patents may be more relevant to current freedom-to-operate analysis than US 5,630,796.

How strong was the patent estate for high-velocity powder delivery?

Historically, US 5,630,796 had meaningful conceptual breadth because it claimed performance characteristics rather than a single drug or device architecture. The scope reached multiple therapeutic agents and delivery mechanisms if the claimed particle and impact parameters were met.

Its limitations were also substantial:

It required actual transdermal crossing of skin;
It required high particle velocity or specified momentum density;
It required particle-size compliance;
It did not directly claim the injector hardware;
It did not claim a broad composition independent of use;
It did not cover passive transdermal systems; and
It did not cover liquid jet injection unless powdered particles were used.

The patent’s practical strength declined after expiration. Current risk depends on later patents covering:

Gas cartridges and acceleration chambers;
Nozzle geometry;
Particle loading and metering;
Drug stabilization;
Spherical-shell or hollow particles;
Skin targeting and dosing control;
Disposable injector components;
Combination products; and
Specific vaccine, insulin, or biologic formulations.

Does the patent create biosimilar or generic entry risk?

US 5,630,796 does not create a current biosimilar or generic-entry barrier. It expired in 2015 and does not claim a biologic molecule, insulin analog, or approved reference product.

For a modern insulin or biologic delivered by powder injection, the relevant risks would arise from later patents covering the active ingredient, excipients, particle engineering, device, dose-control system, or approved method of use. Biosimilar applicants would evaluate those rights under the Biologics Price Competition and Innovation Act, while small-molecule applicants would evaluate listed patents under Hatch-Waxman.

What geographic coverage did the patent provide?

US 5,630,796 provided rights only in the United States. Related applications or patents may have existed in other jurisdictions, but a US patent does not establish European, Canadian, Japanese, Australian, or other territorial rights.

Foreign freedom-to-operate analysis must be conducted separately by jurisdiction. Because patent terms, prosecution outcomes, maintenance payments, claim scope, and litigation histories vary by country, the US expiration date cannot be applied globally.

What manufacturing and IP barriers remain after expiration?

The expired patent does not remove technical barriers. High-velocity powder delivery still requires control over:

Particle size and morphology;
Powder flow and metering;
Particle acceleration;
Impact energy;
Skin penetration depth;
Dose uniformity;
Device safety;
Stability and moisture control;
Sterility or bioburden control; and
Combination-product manufacturing.

Those technical features may be covered by later patents, trade secrets, regulatory approvals, or manufacturing know-how. A company can practice the expired claims without authorization from the original patent owner, but it may still infringe later patents in the same platform.

Key Takeaways

US 5,630,796 covers high-velocity transdermal delivery of powdered therapeutic particles.
Its independent claim groups use either velocity and density or momentum density.
Dependent claims cover insulin, human treatment, narrow particle sizes, spherical shells, stable dry mixtures, and inert carriers.
The patent does not claim a particular injector, drug molecule, disease, or broad powder composition.
The US patent expired in 2015.
It has no current Orange Book exclusivity effect and does not create current Paragraph IV or biosimilar-entry risk.
Current freedom-to-operate risk must focus on later device, formulation, particle-engineering, manufacturing, and combination-product patents.
Foreign rights require separate country-by-country analysis.
The patent remains relevant as prior art and as a historical foundation for the PowderJect high-velocity powder-delivery platform.

FAQs

Is US 5,630,796 still enforceable against a new powder injector?

No. The US patent expired in 2015 and does not provide a current prospective exclusion right.

Does US 5,630,796 cover needle-free liquid injection?

No. The claims require particles of a powdered therapeutic agent. A liquid jet system without powdered drug particles does not meet the express claim format.

Does the patent cover all transdermal insulin delivery?

No. Claim 7 covers insulin only when used in the claimed high-velocity powdered-particle transdermal method.

Could a modern device infringe later patents even if it does not infringe US 5,630,796?

Yes. Later patents may cover injector architecture, powder metering, particle morphology, formulation stabilization, dosing control, or combination-product features.

Is momentum density the same as particle velocity?

No. Momentum density depends on particle mass and delivery flux as well as velocity. A system’s velocity alone does not establish compliance with claims 10, 11, or 14.

References

Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
Novartis AG. (2006). Novartis completes acquisition of Chiron Corporation. Novartis.
U.S. Patent No. 5,630,796. (1997). Transdermal delivery of powdered medicaments. United States Patent and Trademark Office.
21 U.S.C. § 355. (2024). New drugs.
35 U.S.C. § 154. (2024). Contents and term of patents; provisional rights.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9307459	Apr 08, 1993
United Kingdom	9318407	Sep 06, 1993
United Kingdom	9321356	Oct 15, 1993
United Kingdom	9326069	Dec 21, 1993

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	148497	⤷ Start Trial
Austria	329006	⤷ Start Trial
Australia	6435194	⤷ Start Trial
Australia	674742	⤷ Start Trial
Bulgaria	100047	⤷ Start Trial
Bulgaria	61993	⤷ Start Trial
Brazil	9406455	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,630,796

Summary for Patent: 5,630,796